IN2014CN02152A - - Google Patents

Download PDF

Info

Publication number
IN2014CN02152A
IN2014CN02152A IN2152CHN2014A IN2014CN02152A IN 2014CN02152 A IN2014CN02152 A IN 2014CN02152A IN 2152CHN2014 A IN2152CHN2014 A IN 2152CHN2014A IN 2014CN02152 A IN2014CN02152 A IN 2014CN02152A
Authority
IN
India
Prior art keywords
metal salt
aureus
adsorbed
agonist
tlr agonist
Prior art date
Application number
Inventor
Fabio Bagnoli
Barbara Baudner
Simone Bufali
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2014CN02152A publication Critical patent/IN2014CN02152A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The efficacy of S.aureus vaccines can be enhanced by adjuvanting S.aureus antigens with a mixture of a TLR agonist (preferably a TLR7 agonist) and an insoluble metal salt (preferably an aluminium salt). The TLR agonist is typically adsorbed to the metal salt. A S.aureus antigen can also be adsorbed to the metal salt.
IN2152CHN2014 2011-09-01 2012-08-31 IN2014CN02152A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161530162P 2011-09-01 2011-09-01
US201261607999P 2012-03-07 2012-03-07
PCT/EP2012/067032 WO2013030378A1 (en) 2011-09-01 2012-08-31 Adjuvanted formulations of staphylococcus aureus antigens

Publications (1)

Publication Number Publication Date
IN2014CN02152A true IN2014CN02152A (en) 2015-09-04

Family

ID=46763095

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2152CHN2014 IN2014CN02152A (en) 2011-09-01 2012-08-31

Country Status (14)

Country Link
US (1) US20140363461A1 (en)
EP (1) EP2763695A1 (en)
JP (1) JP2014525429A (en)
KR (1) KR20140066212A (en)
CN (1) CN104093418A (en)
AU (1) AU2012300765A1 (en)
BR (1) BR112014004782A2 (en)
CA (1) CA2847204A1 (en)
IL (1) IL231104A0 (en)
IN (1) IN2014CN02152A (en)
MX (1) MX2014002363A (en)
RU (1) RU2014112343A (en)
SG (1) SG11201400210RA (en)
WO (1) WO2013030378A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010115175A1 (en) * 2009-04-03 2010-10-07 Momenta Pharmaceticals, Inc. Control of copolymer compositions
CN102844047B (en) 2009-09-02 2017-04-05 诺华股份有限公司 Immunogenic composition containing TLR active regulators
ES2458355T3 (en) 2010-09-01 2014-05-05 Novartis Ag Adsorption of immunopotentiators on insoluble metal salts
JP2014507142A (en) * 2011-02-08 2014-03-27 インテグレイテッド バイオセラピューティクス，インコーポレイテッド Immunogenic composition comprising alpha hemolysin oligopeptide
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
IN2014CN02152A (en) * 2011-09-01 2015-09-04 Novartis Ag
PL2822947T3 (en) * 2012-03-07 2017-01-31 Glaxosmithkline Biologicals Sa Arginine salts of a tlr7 agonist
AU2013229432A1 (en) 2012-03-08 2014-10-16 Novartis Ag Adjuvanted formulations of booster vaccines
CN110563818A (en) * 2012-08-31 2019-12-13 诺华股份有限公司 Stabilized proteins for immunization against staphylococcus aureus
CN104684570A (en) * 2012-08-31 2015-06-03 诺华股份有限公司 Stabilised proteins for immunising against staphylococcus aureus
WO2014033192A1 (en) * 2012-08-31 2014-03-06 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
WO2015140108A1 (en) * 2014-03-17 2015-09-24 Gaxosmithkline Biologicals Sa Immunising against staphylococcal bone and joint infections
EA037818B1 (en) 2014-03-26 2021-05-25 Глаксосмитклайн Байолоджикалс С.А. Mutant staphylococcal antigens
WO2015144691A1 (en) * 2014-03-26 2015-10-01 Glaxosmithkline Biologicals Sa Compositions for immunising against staphylococcus aureus
CN105646681B (en) * 2016-01-21 2021-07-16 浙江海隆生物科技有限公司 Preparation method and application of staphylococcus aureus alpha-hemolysin subunit vaccine for dairy cows
EP3484518B1 (en) 2016-07-07 2024-08-14 The Board of Trustees of the Leland Stanford Junior University Antibody adjuvant conjugates
AR111760A1 (en) * 2017-05-19 2019-08-14 Novartis Ag COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF SOLID TUMORS THROUGH INTRATUMORAL ADMINISTRATION
CN113993549A (en) 2019-03-15 2022-01-28 博尔特生物治疗药物有限公司 Immunoconjugates targeting HER2

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0114787B1 (en) 1983-01-25 1991-09-25 Ciba-Geigy Ag Peptide derivatives
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
SG48309A1 (en) 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
CA2532370A1 (en) 2003-07-24 2005-02-03 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
WO2005009378A2 (en) 2003-07-24 2005-02-03 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
EP1725575B1 (en) 2004-02-18 2012-11-28 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against staphylococcus aureus
TWI382019B (en) 2005-08-19 2013-01-11 Array Biopharma Inc Aminodiazepines as toll-like receptor modulators
TW200801003A (en) 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
US20090192153A1 (en) 2005-09-22 2009-07-30 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel adenine compound
TW200745114A (en) 2005-09-22 2007-12-16 Astrazeneca Ab Novel compounds
EP1939201A4 (en) 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co Novel adenine compound
JPWO2007034817A1 (en) 2005-09-22 2009-03-26 大日本住友製薬株式会社 New adenine compounds
WO2007034916A1 (en) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. Novel adenine compound
MX2008010611A (en) 2006-02-17 2008-11-12 Pfizer Ltd 3 -deazapurine derivatives as tlr7 modulators.
CN101466406B (en) 2006-06-12 2012-06-27 葛兰素史密斯克蓝生物品公司 Use of alpha-toxin for treating and preventing staphylococcus infections
EP2041135A4 (en) 2006-07-05 2010-12-01 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of tlr7
WO2008005555A1 (en) 2006-07-07 2008-01-10 Gilead Sciences, Inc. Modulators of toll-like receptor 7
WO2008152447A2 (en) 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
DE602008003764D1 (en) 2007-02-19 2011-01-13 Glaxosmithkline Llc PURE DERIVATIVES AS IMMUNOMODULATORS
AR065784A1 (en) 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co DERIVATIVES OF 8-OXO ADENINE, DRUGS THAT CONTAIN THEM AND USES AS THERAPEUTIC AGENTS FOR ALLERGIC, ANTIVIRAL OR ANTIBACTERIAL DISEASES.
BRPI0811125A2 (en) 2007-05-08 2017-05-09 Astrazeneca Ab imidazoquinolines with immunomodulatory properties
CA2707030A1 (en) 2007-08-03 2009-02-12 Pfizer Limited Imidazopyridinones
WO2009029831A1 (en) 2007-08-31 2009-03-05 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
PE20091236A1 (en) 2007-11-22 2009-09-16 Astrazeneca Ab PYRIMIDINE DERIVATIVES AS IMMUNOMODULATORS OF TLR7
WO2009111337A1 (en) 2008-03-03 2009-09-11 Irm Llc Compounds and compositions as tlr activity modulators
PT2276486E (en) 2008-03-24 2013-12-04 4Sc Discovery Gmbh Novel substituted imidazoquinolines
EP2313111B1 (en) 2008-08-01 2013-09-04 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
EA021377B9 (en) 2008-12-09 2015-09-30 Джилид Сайэнс, Инк. Modulators of toll-like receptors
SG175092A1 (en) * 2009-04-14 2011-11-28 Novartis Ag Compositions for immunising against staphylococcus aerus
TWI469789B (en) * 2009-06-22 2015-01-21 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
ES2625979T3 (en) 2009-07-16 2017-07-21 Glaxosmithkline Biologicals S.A. Infection treatment
GB0913681D0 (en) * 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
TWI445708B (en) 2009-09-02 2014-07-21 Irm Llc Compounds and compositions as tlr activity modulators
CN102844047B (en) 2009-09-02 2017-04-05 诺华股份有限公司 Immunogenic composition containing TLR active regulators
EA031379B1 (en) 2010-03-23 2018-12-28 Новартис Аг Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
ES2458355T3 (en) * 2010-09-01 2014-05-05 Novartis Ag Adsorption of immunopotentiators on insoluble metal salts
US20140112950A1 (en) * 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
IN2014CN02152A (en) * 2011-09-01 2015-09-04 Novartis Ag
EP2822586A1 (en) * 2012-03-07 2015-01-14 Novartis AG Adjuvanted formulations of streptococcus pneumoniae antigens
AU2013229432A1 (en) * 2012-03-08 2014-10-16 Novartis Ag Adjuvanted formulations of booster vaccines
JP2015509963A (en) * 2012-03-08 2015-04-02 ノバルティス アーゲー Combination vaccine containing a TLR4 agonist
CN110563818A (en) * 2012-08-31 2019-12-13 诺华股份有限公司 Stabilized proteins for immunization against staphylococcus aureus
WO2014033192A1 (en) * 2012-08-31 2014-03-06 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
JP2015528456A (en) * 2012-08-31 2015-09-28 ノバルティス アーゲー Stabilized protein for immunization against STAPHYLOCOCUSAUREUS
CN104684570A (en) * 2012-08-31 2015-06-03 诺华股份有限公司 Stabilised proteins for immunising against staphylococcus aureus
JP6324961B2 (en) * 2012-09-06 2018-05-16 ノバルティス アーゲー Combination vaccine of serogroup B meningococcus and D / T / P
GB201219420D0 (en) * 2012-10-29 2012-12-12 Novartis Ag Staphyloccal immunogens
EP2950819B1 (en) * 2013-02-01 2018-03-28 GlaxoSmithKline Biologicals SA Intradermal delivery of immunological compositions comprising toll-like receptor agonists
WO2015140108A1 (en) * 2014-03-17 2015-09-24 Gaxosmithkline Biologicals Sa Immunising against staphylococcal bone and joint infections
WO2015144691A1 (en) * 2014-03-26 2015-10-01 Glaxosmithkline Biologicals Sa Compositions for immunising against staphylococcus aureus
EA037818B1 (en) * 2014-03-26 2021-05-25 Глаксосмитклайн Байолоджикалс С.А. Mutant staphylococcal antigens

Also Published As

Publication number Publication date
IL231104A0 (en) 2014-04-30
CN104093418A (en) 2014-10-08
CA2847204A1 (en) 2013-03-07
SG11201400210RA (en) 2014-03-28
JP2014525429A (en) 2014-09-29
AU2012300765A1 (en) 2014-03-13
BR112014004782A2 (en) 2017-03-21
US20140363461A1 (en) 2014-12-11
EP2763695A1 (en) 2014-08-13
WO2013030378A1 (en) 2013-03-07
RU2014112343A (en) 2015-10-10
MX2014002363A (en) 2014-04-14
KR20140066212A (en) 2014-05-30

Similar Documents

Publication Publication Date Title
IN2014CN02152A (en)
ZA201500316B (en) Novel compound with effects of thrombolysis, free radical scavenging and thrombus-targeting as well as preparation method and use thereof
EP2680885B8 (en) Combination vaccines with lower doses of antigen and/or adjuvant
MX2015014500A (en) Combination therapy of antibodies against human csf-1r and tlr9 agonist.
IN2014CN03143A (en)
EP2997246A4 (en) Piston having combustion bowl shaped to balance combustion efficiency and emission properties
EP2992089A4 (en) Use of anti-cd47 agents to enhance immunization
NZ705606A (en) Methods for identifying antibodies with reduced immunogenicity
IL231282A0 (en) Antibodies to pcsk9 and uses thereof
ZA201308022B (en) Anti-cd40 antibodies and methods of use
TWD158794S (en) Concealer container
MX2013008390A (en) Preparation of metal-triazolate frameworks.
EP2788376A4 (en) Neutralizing antibodies to hiv-1 and their use
MY168362A (en) An aerosol generating device having an internal heater
BR112014031310A2 (en) anti-pcsk9 antibodies, formulations, dosage and methods of use
IN2014DN03208A (en)
EP3089982A4 (en) 7-beta analogs of orvinols
WO2014144061A9 (en) Flavivirus neutralizing antibodies and methods of use thereof
IN2014CN03454A (en)
WO2013033496A3 (en) Laser adjuvants for enhancing immune response
TWD169462S (en) Male connector
EP2726499A4 (en) Epitope and its use of hepatitis b virus surface antigen
EP2999866A4 (en) One-stroke internal combustion engine
EP3010934A4 (en) Antibodies to human resistin
EP2970462A4 (en) Anti-rankl antibodies and methods of use